Affordable Access

Access to the full text

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

Authors
  • Tarantelli, Chiara
  • Lupia, Antonio
  • Stathis, Anastasios1
  • Bertoni, Francesco
  • 1 Faculty of Biomedical Sciences, USI, 6900 Lugano, Switzerland
Type
Published Article
Journal
International Journal of Molecular Sciences
Publisher
MDPI AG
Publication Date
Feb 05, 2020
Volume
21
Issue
3
Identifiers
DOI: 10.3390/ijms21031060
PMID: 32033478
PMCID: PMC7037719
Source
PubMed Central
Keywords
License
Green

Abstract

The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.

Report this publication

Statistics

Seen <100 times